HA/CS NPs were loaded with a challenging water-insoluble drug, Everolimus (EVE), an antiproliferative agent currently approved by many agencies for treatment of advanced cancers [39], most of them characterized by CD44-overexpressing feature. This evidence concerns the gene CD44 and cancer.